He has graduated (in 1980) the First Moscow State Medical University (Sechenov University), where he later worked (1980-2012).
He is the Candidate of Medical Science (1985) and the Doctor of Medicine (2001).
Since 2013 – the Director General of the Federal State Budgetary Scientific Institution «Chumakov Federal Scientific Center for Research & Development of Immune-and-Biological Product» (FSBSI Chumakov FSC R&D IBP RAS) of the Ministry of Science and Higher Education (Russia). Since 2017 – the head of the subdepartment of the organization and technology of immunobiological preparations production of the First Moscow State Medical University.
Was chosen as the RAS corresponding member in medical sciences department («Pharmacy Organization» specialty) (2016).
Under the leadership of A.A. Ishmukhametov there was developed a unique methodology for the production of information and analytical systems reflecting the actual state of the pharmaceutical industry. It includes the latest statistical data processing techniques and data extrapolation algorithms adapted to the characteristics of the pharmaceutical market. Creation of a fundamentally new analytical content, enabling multifactor analysis and scientific forecasting of economic phenomena in the pharmaceutical market, makes it possible to more effectively solve the problems of the industry. There are formulated and substantiated the basic principles of creating a unified information environment in the field of circulation of medicines.
In 2014, he proposed and implemented the Chumakov Center development concept, which made it possible to combine the scientific, technological and production aspects of creating and introducing into the circulation the original innovative national immunobiological preparations, such as prevention vaccines for the polio, tick-borne encephalitis, yellow fever, which are included in regional immunization calendars. The reorganization of the enterprise’s business processes has carried out with the introduction of quality management principles in biopharmaceutical enterprises. This has made it possible in the shortest possible time to completely modernize the enterprise, obtain a GMP certificate, solve the problems of import substitution and to develop new biopharmaceutical and immunological preparations, some of which have already passed preclinical and clinical studies. As the result, the company has increased its output and exports of the preparations.